Please Wait
Applying Filters...
menu
    • menu
    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    Menu

    Ibezapolstat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 10,389Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Acurx Publishes Data On Ibezapolstat's Gut Microbiome Effects
    Acurx Publishes Data On Ibezapolstat's Gut Microbiome Effects

    03 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acurx-announces-publication-of-nonclinical-in-vivo-data-differentiating-ibezapolstats-gut-microbiome-effects-from-other-anti-cdi-antibiotics-302386442.html

    PR NEWSWIRE
    03 Mar 2025
    Share Share
    Acurx publishes positive results on Ibezapolstat for CDI.
    Acurx publishes positive results on Ibezapolstat for CDI.

    24 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acurx-announces-publication-of-positive-results-from-an-in-silico-study-predicting-the-microbiome-restorative-potential-of-ibezapolstat-in-the-treatment-of-cdi-302382681.html

    PR NEWSWIRE
    24 Feb 2025
    Share Share
    Acurx Gets EMA Guidance For Ibezapolstat Ph3 For C. Difficile
    Acurx Gets EMA Guidance For Ibezapolstat Ph3 For C. Difficile

    06 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acurx-receives-positive-regulatory-guidance-from-ema-for-ibezapolstat-phase-3-program-for-c-difficile-infection-cdi-302342404.html

    PR NEWSWIRE
    06 Jan 2025
    Share Share
    Acurx Updates Phase 3 Readiness for Ibezapolstat in C. Difficile
    Acurx Updates Phase 3 Readiness for Ibezapolstat in C. Difficile

    09 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acurx-updates-phase-3-readiness-for-ibezapolstat-in-c-difficile-infection-based-on-recent-fda-and-ema-communications-302325768.html

    PR NEWSWIRE
    09 Dec 2024
    Share Share
    Acurx Announces Ibezapolstat And ACX-375 Results in CDI
    Acurx Announces Ibezapolstat And ACX-375 Results in CDI

    26 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acurx-announces-additional-ibezapolstat-ph2b-results-in-cdi-as-well-as-anthrax-b-anthracis-susceptibility-to-acx-375-analogues-302259491.html

    PR NEWSWIRE
    26 Sep 2024
    Share Share
    Acurx Shares Ibezapolstat Research at International C. difficile Symposium
    Acurx Shares Ibezapolstat Research at International C. difficile Symposium

    24 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acurx-announces-results-of-its-pioneering-research-with-ibezapolstat-in-collaboration-with-leiden-university-medical-center-at-the-premier-international-c-difficile-symposium-302256562.html

    PR NEWSWIRE
    24 Sep 2024
    Share Share